![First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-02561-z/MediaObjects/41598_2021_2561_Fig2_HTML.png)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
![Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09741-8/MediaObjects/12885_2022_9741_Fig5_HTML.png)
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study | PLOS ONE
![Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram](https://www.researchgate.net/publication/351356511/figure/fig3/AS:1020344911544323@1620280592069/Kaplan-Meyer-curves-for-progression-free-survival-of-osimertinib-by-a-SD-PD-versus.png)
Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram
![First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-02561-z/MediaObjects/41598_2021_2561_Fig1_HTML.png)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
![Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer](https://www.lungcancerjournal.info/cms/asset/cc0a6162-14b5-4b9d-ac61-e5064efad248/gr1.jpg)
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer
![Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00794-6/MediaObjects/11523_2021_794_Fig1_HTML.png)
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
![An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC) An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)](https://www.ilcn.org/wp-content/uploads/2021/12/ADAURA.jpg)
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
![ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC](https://dailynews.ascopubs.org/do/10.1200/ADN.20.200207/full/dn_figure-1592894387557.jpg)
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
![New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/graph.png/jcr:content/renditions/cq5dam.web.320.graph.png)
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
![Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer](https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2016/AURA3.png/jcr:content/renditions/cq5dam.web.480.AURA3.png)
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
![FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC - Daily Reporter FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC - Daily Reporter](https://dailyreporter.esmo.org/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/video/flaura-trial-overall-survival-results-confirms-the-efficacy-of-osimertinib-in-the-treatment-of-nsclc/8737972-3-eng-GB/flaura-trial-overall-survival-results-confirms-the-efficacy-of-osimertinib-in-the-treatment-of-nsclc_i770.png)
FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC - Daily Reporter
![Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis - Zhao - 2022 - International Journal of Cancer - Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis - Zhao - 2022 - International Journal of Cancer -](https://onlinelibrary.wiley.com/cms/asset/2b2484b2-30d1-4a1e-943f-7b06950af24d/ijc33904-toc-0001-m.jpg)
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis - Zhao - 2022 - International Journal of Cancer -
![VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC #StudyGraphics #lungcancer | Tyrosine, Survival, Medicine VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC #StudyGraphics #lungcancer | Tyrosine, Survival, Medicine](https://i.pinimg.com/originals/31/58/68/315868021cb7409ea55b49e5a09c8562.jpg)